Kornimate/medical-research-clean huggingface dataset:
relationship between oral health status and unexplained female infertility in turkish population

Conditions: Dental Caries; Female Infertility

Summary: periodontal diseases and dental caries are initiated by a pathogenic biofilm, in a susceptible host, affecting the tooth periodontium and hard tissues. its possible association with many biologic systems has been studied. in this study, researchers investigated association between oral health and female infertility, and what is the biological rationale for such relationship.

power analysis was performed with the g-power software package to determine sample size. to cover possible data loss, 10% of a group were added to each group. medical and dental examination will be performed both of control and experimental groups. in dental examination decayed, missing, or filled teeth (dmft) index will be used according to world health organization (who 1997) criteria. all teeth were visually using the international caries detection and assessment system (icdas-ii). to analyze the correlation between oral health status and female infertility linear regression test and for comparison of both the groups (case and control), two sample t test and chi square test were used.

Eligibility criteria:
inclusion criteria: * women who had regular menses and can't conceive despite a long-term regular sexual intercourse for more than 12 months * women with normal hormone values and uterine cavity with at least one healthy fallopian tube. * all male partners have a semen specimen with minimum 5 million motile sperm in the ejaculate. * the control group members have minimum two normal pregnancies exclusion criteria: * patients who have history of f; hydrosalpinx, polycystic ovarian syndrome, endometriosis grade 3-4, thyroid disease, tubal surgery, hyperprolactinemia, autoimmune diseases, diabetes mellitus, uterine/cervical anomalies, active liver disease, cardiovascular disease, premature ovarian failure, smoking and alcohol consumption, poor socioeconomic level, hiv-infected, obesity (body mass index ≥ 30 kg/m2), chronic upper respiratory tract diseases and dental fluorosis. * patients using fluoride supplements and orthodontic appliances
perception prognosis, goals of treatment, and communication

Conditions: Gastric Cancer; Esophageal Cancer; Pancreatic Cancer; Liver Cancer; Biliary Cancer

Summary: the purpose of this research study is to assess what the participant understands about their illness, prognosis, the goals of the cancer treatment and their communication with their oncology providers. this study will help us to figure out how the investigators can improve how other patients understand their illness and goals of treatment and help us improve communication with their doctors. this research is being done because there is not a lot of information on how much patients understand about their illness and prognosis.

* participants will be asked to answer a few basic questions regarding race, ethnicity, religion, relationship status, education, income, and living situation. * they will then be asked to complete a questionnaire which contains questions about their mood, spirituality, quality of life and their understanding of their treatment and prognosis and their communication with their oncologist. they will complete these questionnaires in the clinic or infusion room on one of their regularly scheduled visit.

Eligibility criteria:
inclusion criteria: * confirmed new diagnosis of advanced gastric, esophageal, pancreatic, and hepatobiliary cancer, not being treated with curative intent. * planning to receive chemotherapy at massachusetts general hospital * ability to read and respond to questions in english. exclusion criteria: * prior chemotherapy for current stage of disease.

Keywords: advanced cancer
behavioral and recovery support for 30 day post-discharge care

Conditions: Cardiovascular Diseases

Summary: this study will provide behavioral and mental health support to a select group of participants to supplement the hospital-provided discharge and recovery plans, based on clinical guidance and dedicated post-hospitalization behavioral protocols, with the goals of reducing readmission rates and costs.

this study was designed to provide support to a select group of participants by supplementing the hospital-provided discharge instructions. laguna integrated clinical guidance and dedicated post-hospitalization laguna recovery protocols, with the aims of improving health outcomes, reducing health costs, and reducing readmission rates within 30 days post-discharge. participants in the intervention group received support from laguna health via phone, video, text, or web chat. laguna provided contextual support to remove recovery barriers to these intervention participants.

Eligibility criteria:
inclusion criteria: * admitted to the hospital with a diagnosis of a cardiovascular disease * discharged to home * converse in english or spanish * uses a telephone exclusion criteria: * participant unable to provide informed consent * participant lacks cognitive ability to participate in the study interventions as judged by the primary attending physician

Keywords: readmissions cardiovascular post-discharge behavioral health readmission cost 30 day readmission heart failure care management barriers to care contextualizing healthcare
anti-tumor immune response in patients with cancer undergoing radiation therapy

Conditions: Malignant Neoplasm

Summary: this research trial studies the effect of radiation therapy on tumor immunity. standard radiation therapy destroys tumor cells. in response to tumor cell death caused by radiation therapy, the body has an ability to stimulate an anti-tumor response (immunity), but this response is often ineffective in shrinking tumor tissue. collecting samples of blood from patients before, during, and after radiation therapy to study in the laboratory may help doctors learn more about the effects of radiation therapy on anti-tumor response.

primary objectives: i. to assess the effect of radiation therapy on tumor immunity. outline: samples of blood are collected before, during, and within two weeks after radiation therapy and then stored for analysis of anti-tumor immunity.

Eligibility criteria:
inclusion criteria: * signed and dated institutional review board (irb)-approved informed consent form for the study * received an explanation of the study, including satisfactory answers to all questions related to the proposed research * is undergoing physician directed radiation treatment exclusion criteria: * the potential subject is unwilling or hesitant to participate for any reason and/or fails to complete the appropriate informed consent form
the distribution of body constitutions among hong kong elderly population: a cross-sectional study

Conditions: Nine Body Constitutions

Summary: hong kong, similar as other developed economic entities, has been faced big challenges from increasing medical burden and aged population. based on the updated estimates of domestic health expenditure by food and health bureau hksar, the total health expenditure amounted to hk$112,144 million in 2012/13 with increasing approximate 4 times than 1992/93. according to the data from census and statistics department, in 2010, there was still 13% population aged above 65 years, while in 2039, this percentage will be elevated to 28% (http://www.censtatd.gov.hk/hkstat/sub/so20.jsp). in other words, every three individuals will contain a person aged above 65 years in the future 30 years. therefore, how to release the medical burden resulted from aged tendency of population is the critical question in optimizing the treatment expenses. our aims in the cross-sectional study are to 1) estimate the number and percentage of nine body constitutions among population aged 65 and over in hong kong 2) identify the associations between nine body constitutions and other predetermined factors such as gender, weight, diet, body mass index (bmi), blood pressure, quality of life scale scores, et al.


Eligibility criteria:
inclusion criteria: * aged 65 and over * capable of consenting and have agreed to participate, ambulatory, and not receiving treatment modalities, which, if omitted, may result in immediate life threatening risk such as chemotherapy or radiotherapy for cancer, or dialysis for renal failure exclusion criteria: * neurological disorders such as dementia
the optimal duration of dual antiplatelet therapy after implantation of endeavor stent

Conditions: Coronary Artery Disease

Summary: the purpose of this study to determine whether the dual antiplatelet therapy (aspirin and clopidogrel) for 3 months after coronary implantation of zotarolimus-eluting stent is safe in terms of death, myocardial infarction, or stent thrombosis.


Eligibility criteria:
inclusion criteria: * patients with clinically significant de novo coronary artery disease * stenting only with endeavor® stents * the sum of stent length is less than 60 mm for one lesion. the sum of stent length in multiple lesions does not matter. exclusion criteria: * cardiogenic shock * st-elevation myocardial infarction within 48 hours of symptom onset * prior implantation of drug-eluting stents * left ventricular dysfunction (echocardiographic left ventricular ejection fraction \< 25%) * stenting both branch of bifurcation lesion * left main trunk lesion * graft vessels * patients who have to receive clopidogrel due to other conditions * patients who have to receive warfarin, cilostazol or other antiplatelet therapy * patient with chronic renal failure (s-cr \> 2.0 mg/dl) * hypersensitivity to clopidogrel or aspirin * expectant survival less than 1 year * women who plan to become pregnant * patients with bleeding diathesis (coagulopathy, thrombocytopenia or platelet dysfunction, gastrointestinal or genitourinary bleeding within the prior 3 months) * patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period.

Keywords: angioplasty, transluminal, percutaneous coronary stent thrombosis zotarolimus-eluting stent
tafluprost-timolol preservative-free fixed dose combination (fdc) superiority study against monotherapies

Conditions: Ocular Hypertension; Open-angle Glaucoma

Summary: the purpose of this study is to compare the efficacy and safety of the preservative-free fixed tafluprost-timolol combination to those of tafluprost and timolol alone. this study will enroll patients who have ocular hypertension or glaucoma and who are using timolol or prostaglandin. the study medication period is 6 months, but the primary evaluation of efficacy is done at 3 months.


Eligibility criteria:
inclusion criteria: * aged 18 years or more * a diagnosis of ocular hypertension or open-angle glaucoma and prior use of timolol or prostaglandin. * meet specific iop level at visit 1 (screening), visit 2 (run-in) and visit 3 (baseline). * meet specific visual acuity score * are willing to follow instructions * have provided a written informed consent exclusion criteria: * females who are pregnant, nursing or planning pregnancy * iop of 35 mmhg or greater * diagnosis of angle-closure glaucoma or secondary glaucoma other than capsular or pigmentary glaucoma in either eye * suspected contraindication or hypersensitivity to study medications tafluprost or timolol (e.g. asthma, low pulse)or to wash-out medication brinzolamide * glaucoma filtration surgery or any other ocular surgery (including ocular laser procedures) within 6 months prior to screening * use of contact lenses at screening or during the study * presence of any abnormality or significant illness that could be expected to interfere with the patient safety or study parameters * current participation in another clinical trial within the last 30 days
validity of a belt mounted accelerometer to assess walking measures in patients with chronic stroke

Conditions: Stroke; Gait, Hemiplegic

Summary: the aim of this study is to validate the g-walk for several gait parameters, tested against a gold standard three dimensional camera system. this research will inform researchers and practitioners as to whether the g-walk is a suitable and valid tool to easily assess walking ability in people with chronic stroke.

twenty chronic stroke survivors will be recruited for this study from an independent neuro-physiotherapy practice and community exercise programme.gait analysis will be used to look at several gait parameters through the use of a three-dimensional visual analysis system based in our biomechanics lab at the university of winchester. participants will attend testing one testing session of approximately 1 hour. during this testing session functional measures and walking trials will be assessed. participants will first be asked to complete a set of simple movements that will contribute towards fugl meyer questionnaire. twenty eight reflective markers will then be attached to specified joints and segments of the body, such as the thigh, with double sided sticky tape to allow for data collection through the camera system to collect kinematic data. the belt mounted accelerometer (g-walk) will be positioned around the waist over the l5 vertebrae. participants will be asked to perform 6 walking trials of 10m to collect 3d kinematic and accelerometer gait data.

Eligibility criteria:
inclusion criteria: * \<3 months post stroke * lower limb impairment * able to stand and step independently * functional ambulation classifications (fac) of 2-5 * modified rankin scale (mrs) of 1-3 * cognitively aware to undertake the testing session exclusion criteria: * unresolved deep vein thrombosis * unstable cardiovascular conditions * open wounds * active drug resistant infection * recent fractures of involved limb * peripheral arterial disease * incontinence * severe osteoporosis * non-weight bearing.

Keywords: stroke validity gait
interactive multirisk-factor intervention for hypertension (htn) blacks

Conditions: Hypertension

Summary: the aim of this study is to assess the efficacy of telephone-linked_care for hypertension regimen adherence in an african american population (tlc-htn-aa). tlc-htn-aa is a computer-based telecommunication system that will monitor, educate and counsel african american adults with hypertension on adherence to medication, diet, and exercise. the primary hypotheses are: 1. tlc-htn-aa use will improve medication regiment adherence 2. tlc-htn-aa will improve adherence to 3 healthy diet recommendations 3. tlc-htn-aa will improve levels of regular exercise 4. patients receiving tlc-htn-aa will be more likely to become adherent to all 3 target regiments than patients in the control group


Eligibility criteria:
inclusion criteria: * a patient with a primary care provider at one of boston medical center's adult primary care medical practices or one of three healthnet health centers participating in the study * have a physician diagnosis of hypertension * be african american by self-report * be 35 years of age or older * be prescribed at least one medication for hypertension * have poorly controlled blood pressure * be non-adherent to at least one hypertensive medication * understand spoken english * have a home telephone exclusion criteria: * patients for whom a medication, diet or exercise regiment adherence improvement or maintenance program would be inappropriate * patients with a terminal illness * patients with severe medical or psychiatric illness * patients with cognitive difficulty
safety and efficacy of valsartan and amlodipine combined and alone in patients with hypertension.

Conditions: Hypertension

Summary: this trial will compare valsartan and amlodipine combination therapies to both valsartan and amlodipine, and placebo for the treatment of hypertension.


Eligibility criteria:
inclusion criteria: * outpatients 18 years and older. * male or female patients are eligible. * female patients must be either post-menopausal for one year or surgically sterile, or using effective contraceptive methods such as barrier method with spermicide or an intra-uterine device. hormonal contraceptive use is disallowed. * patients with mild to moderate essential diastolic hypertension (grades 1 and 2 who classification) measured by calibrated standard sphygmomanometer. * patients must have a msdbp \>= 90 mmhg and \ = 95 mmhg and \< 110 mmhg at visit 2 (week 0). * patients must have an absolute difference of =\< 10 mmhg in their average sitting diastolic blood pressure between visits 1 and 2. * patients who are eligible and able to participate in the study, and who consent to do so after the purpose and nature of the investigation has been clearly explained to them (written informed consent). exclusion criteria: * severe hypertension (grade 3 who classification; msdbp \>=110 mmhg diastolic and/or mssbp \>= 180 mmhg systolic). * inability to discontinue all prior anti-hypertensive medications safely for a period of 14 weeks). * known keith-wagener grade iii or iv hypertensive retinopathy. * history of hypertensive encephalopathy or cerebrovascular accident at anytime prior to visit 1 (week -2 to -4). * transient ischemic cerebral attack during the last 12 months prior to visit 1 (week -2 to -4). * evidence of a secondary form of hypertension, such as coarctation of the aorta, hyperaldosteronism, unilateral renal artery stenosis, or pheochromocytoma, etc. * type 1 diabetes mellitus. * type 2 diabetes mellitus with poor glucose control as defined by fasting glycosylated hemoglobin (hba1c) \>8% at visit 1 (week -2 to -4). * administration of any agent indicated for the treatment of hypertension within a minimum 4 weeks prior to randomization into the study (visit 2, week 0), with the permitted exception of those anti-hypertensive medications requiring tapering down commencing at visit 0 (week -4 to -6). * known or suspected contraindications, including history of allergy to angiotensin receptor blockers or calcium channel blockers. * other protocol-defined inclusion/exclusion criteria may apply

Keywords: hyeprtension, valsartan, amlodipine, high blood pressure
barostim® hope for heart failure study

Conditions: Heart Failure

Summary: the purpose of this clinical investigation is to assess the long-term safety and efficacy of the barostim neo system in subjects currently participating in the barostim® hope4hf trial (nct01720160).

a prospective, randomized study describing the safety and efficacy of the barostim neo system in heart failure subjects with left ventricular ejection fraction equal to or less than 35 percent. seventy two subjects were randomized; 32 to the medical management arm and 40 to the device arm (38 implanted, 2 withdrawn). the study closed to new enrollments on january 31, 2014. subjects are in long-term follow-up and are required to have at least one annual visit. during the visit, there will be a physical assessment, a review of medications and serious adverse events.

Eligibility criteria:
inclusion criteria: * actively participating in the barostim hope4hf study and currently implanted with the barostim neo device with the device turned on. * have signed a revised approved informed consent form for continued participation in this study. exclusion criteria: • treating physician decision that the subject should not continue with therapy.

Keywords: systolic heart failure congestive heart failure reduced left ventricular ejection fraction hfref
comparison of three noninvasive ventilation modes: a physiological study in healthy volunteers

Conditions: Respiratory Failure; Non Invasive Ventilation on Healthy Volunteer

Summary: noninvasive ventilation (niv) is a well established, safe, and effective technique in improving gas exchange while reducing dyspnea and inspiratory effort in patients with either hypoxemic and hypercapnic acute respiratory failure (arf) and averts the risk secondary to endotracheal intubation.crucial factors for niv success, in any forms of respiratory failure, are the tolerance to the interface used and the ability of the interface to unload inspiratory-muscle. helmet is better tolerated over time, allowing continuous application of niv for longer periods, while face mask has been proved to be more efficient at iso-support in unloading the respiratory muscles and improving patient-ventilator synchrony. helmet next (castar, niv model, starmed, mirandola, italy) is a novel type of helmet with a better compliant wall, that avoid the use of armpit braces potentially improving, compared to the standard helmet, both pressurization and patient-ventilator interaction and tolerance. the objective of this study is to compare the effects of niv delivered via face mask, standard helmet, and next helmet in terms of work of breathing, patient-ventilator interaction, and comfort.

16 healthy volunteers will be enrolled. they will be ventilated with non invasive ventilation. the work of breathing, ventilator/patient asynchrony, and ventilatory comfort produced between face mask, helmet and next helmet will be compared.

Eligibility criteria:
inclusion criteria: * healthy volunteers exclusion criteria: * contraindications for nasogastric tube placement * respiratory disease * pregnancy * no french health insurance

Keywords: non invasive ventilation helmet next helmet work of breathing intensive care
profiling microbiome associated metabolic pathways in oesophageal cancer survivors

Conditions: Oesophageal Cancer; Quality of Life; Bacterial Overgrowth

Summary: the goal of this observational study is to learn about long term symptoms in oesophageal cancer survivors. the main question it aims to answer is are: * study the changes in gut bacteria by examining saliva, stool and blood. * investigate the products of bacteria in breath to develop a non-invasive breath test to detect the changes in gut bacteria. * develop new strategies to treat this change and trial new treatments to improve quality- of-life in oesophageal cancer survivors. participants will attend an outpatient clinic, fasted for at least 4 hours for collection of breath, saliva, blood, urine, stool and complete validated healthy-related quality-of-life questionnaires. researchers will compare symptomatic and asymptomatic participants to detect the changes stated above.


Eligibility criteria:
inclusion criteria: * male and female patients aged 18-90 years * patients who underwent oesophagectomy for oesophageal adenocarcinoma with curative intent * disease free patients (ct with no evidence of recurrence within last 6 months or more than 5 years post oesophageal resection) * patients more than 1 year post oesophageal resection exclusion criteria: * patients with siewert iii gastro-oesophageal junctional tumours * patients with evidence of disease recurrence * patients who are unable or unwilling to provide informed written consent * patients who have received antibiotic therapy within the last 4 weeks